Want to see HK:1672 full AI Analyst Report?

Ascletis Pharma, Inc. (1672) Price & Analysis

9 Followers

1672 Stock Chart & Stats

HK$8.94

-HK$0.23(-2.51%)

At close: Jul 28 4:00 PM EDT

HK$8.94

-HK$0.23(-2.51%)

Day’s Range― - ―

52-Week RangeHK$7.95 - HK$19.86

Previous CloseN/A

Volume1.64M

Average Volume (3M)8.30M

Market Cap

HK$8.77B

Enterprise ValueHK$9.00K

Total Cash (Recent Filing)HK$1.90B

Total Debt (Recent Filing)HK$5.16M

Price to Earnings (P/E)―

Beta1.08

Next Earnings

Aug 31, 2026

EPS Estimate

-0.23

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.37

Shares Outstanding1,057,769,000

10 Day Avg. Volume6,104,199

30 Day Avg. Volume8,303,348

Financial Highlights & Ratios

PEG Ratio-1.18

Price to Book (P/B)5.14

Price to Sales (P/S)4905.97

P/FCF Ratio-30.07

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

HK$12.19

Price Target Upside36.35% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.37

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low LeverageVery low debt levels provide durable solvency protection and financing optionality. With minimal leverage the company has structural flexibility to access capital or extend runway without immediate refinancing pressure, which matters while R&D and commercialization continue.

In-house R&D And CommercializationOwning both R&D and commercialization capabilities creates a lasting competitive advantage: it shortens development-to-market cycles, preserves capture of downstream economics, and enables iterative product development tied to real-world commercial feedback.

Multiple Revenue ChannelsA multi-pronged revenue model (sales, licensing/milestones/royalties, services) provides structural diversification. Licensing and collaborations can monetise pipeline assets even if direct product sales stall, supporting medium-term cash inflows as programs mature.

Bears Say

Collapsed RevenueA dramatic, persistent revenue collapse signals structural commercial issues or loss of key products/markets. Combined with ongoing negative gross profit in 2025, this undermines the business’s ability to cover fixed costs and sustain core operations without material remediation.

Persistent Negative Cash FlowSustained negative OCF and FCF with accelerating burn reduces internal funding for R&D and operations. Over the next several months this structural cash deficit increases dependence on external financing, risking dilution or disrupted programs if capital access tightens.

Eroding Equity And Poor ReturnsDeclining total assets and equity alongside deeply negative ROE reflect ongoing value erosion. This long-term degradation weakens balance sheet resilience and limits the firm’s ability to absorb further losses or pursue growth without dilutive or costly capital solutions.

Ascletis Pharma, Inc. News

Ascletis launches global Phase III obesity trial and advances oral triple agonist portfolio

The latest update is out from Ascletis Pharma, Inc. ( ($HK:1672) ). Ascletis Pharma has launched a global...

3d ago

1672

Ascletis Pharma Schedules Board Meeting to Review 2026 Interim Results and Dividend

Ascletis Pharma, Inc. ( ($HK:1672) ) just unveiled an update. Ascletis Pharma Inc. has announced that its board...

3d ago

1672

Ascletis Advances Once-Monthly Obesity Drug ASC37 With Strong Preclinical Results

Ascletis Pharma, Inc. ( ($HK:1672) ) has issued an announcement. Ascletis Pharma reported new preclinical data showing its...

10d ago

1672

Ascletis Showcases Preclinical Obesity Drug with Superior Weight-Loss Data at EASD 2026

An update from Ascletis Pharma, Inc. ( ($HK:1672) ) is now available. Ascletis Pharma announced that preclinical data...

15d ago

1672

Ascletis Advances First-in-Class Oral GLP/GIP Combo for Obesity

Ascletis Pharma, Inc. ( ($HK:1672) ) just unveiled an announcement. Ascletis has selected a fixed-dose combination of its...

22d ago

1672

Ascletis files U.S. INDs for next‑generation monthly obesity injections

Ascletis Pharma, Inc. ( ($HK:1672) ) has issued an announcement. Ascletis Pharma has submitted two Investigational New Drug...

1M ago

1672

Ascletis Pharma Launches HK$300 Million Share Buyback Under Mandate

An update from Ascletis Pharma, Inc. ( ($HK:1672) ) is now available. Ascletis Pharma Inc. announced that its...

1M ago

1672

Ascletis Pharma Wins Shareholder Backing for All AGM Resolutions and Capital Mandates

The latest update is out from Ascletis Pharma, Inc. ( ($HK:1672) ). Ascletis Pharma shareholders approved all resolutions...

1M ago

1672

Ascletis Wins FDA Green Light for Monthly Obesity Drug ASC35 Phase I Trial

Ascletis Pharma, Inc. ( ($HK:1672) ) just unveiled an update. Ascletis Pharma has received U.S. FDA clearance for...

1M ago

1672

Ascletis Showcases Differentiated Oral Obesity Drugs at ADA 2026

Ascletis Pharma, Inc. ( ($HK:1672) ) has issued an announcement. Ascletis Pharma highlighted progress in its obesity portfolio...

2M ago

1672

1672 FAQ

What was Ascletis Pharma, Inc.’s price range in the past 12 months?

Ascletis Pharma, Inc. lowest stock price was HK$7.95 and its highest was HK$19.86 in the past 12 months.

What is Ascletis Pharma, Inc.’s market cap?

Ascletis Pharma, Inc.’s market cap is HK$8.77B.

When is Ascletis Pharma, Inc.’s upcoming earnings report date?

Ascletis Pharma, Inc.’s upcoming earnings report date is Aug 31, 2026 which is in 25 days.

How were Ascletis Pharma, Inc.’s earnings last quarter?

Ascletis Pharma, Inc. released its earnings results on Mar 31, 2026. The company reported -HK$0.325 earnings per share for the quarter, the consensus estimate of -HK$0.325 by HK$0.

Is Ascletis Pharma, Inc. overvalued?

According to Wall Street analysts Ascletis Pharma, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Ascletis Pharma, Inc. pay dividends?

Ascletis Pharma, Inc. does not currently pay dividends.

What is Ascletis Pharma, Inc.’s EPS estimate?

Ascletis Pharma, Inc.’s EPS estimate is -0.23.

How many shares outstanding does Ascletis Pharma, Inc. have?

Ascletis Pharma, Inc. has 1,057,769,000 shares outstanding.

What happened to Ascletis Pharma, Inc.’s price movement after its last earnings report?

Ascletis Pharma, Inc. reported an EPS of -HK$0.325 in its last earnings report, expectations of -HK$0.325. Following the earnings report the stock price went down -1.129%.

Which hedge fund is a major shareholder of Ascletis Pharma, Inc.?

Currently, no hedge funds are holding shares in HK:1672

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Ascletis Pharma, Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

1.80%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Ascletis Pharma, Inc.

Ascletis Pharma, Inc. (1672) is a biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of therapies, with a primary focus on antiviral and other disease areas. The company develops and markets prescription medicines and related products, and operates through a combination of in-house capabilities and external collaborations to advance drug candidates from clinical development to commercialization.

Ascletis Pharma, Inc. (1672) Earnings & Revenues

Historic Earnings Reports

1672 Stock 12 Month Forecast

Average Price Target

HK$12.19

▲(36.35% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"HK$7","12":"HK$12","17":"HK$17","9.5":"HK$9.5","14.5":"HK$14.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12.19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$12.19</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$12.19</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$12.19</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,9.5,12,14.5,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.35,8.645384615384614,8.94076923076923,9.236153846153845,9.53153846153846,9.826923076923077,10.122307692307691,10.417692307692306,10.713076923076922,11.008461538461539,11.303846153846154,11.599230769230768,11.894615384615385,{"y":12.19,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.35,8.645384615384614,8.94076923076923,9.236153846153845,9.53153846153846,9.826923076923077,10.122307692307691,10.417692307692306,10.713076923076922,11.008461538461539,11.303846153846154,11.599230769230768,11.894615384615385,{"y":12.19,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.35,8.645384615384614,8.94076923076923,9.236153846153845,9.53153846153846,9.826923076923077,10.122307692307691,10.417692307692306,10.713076923076922,11.008461538461539,11.303846153846154,11.599230769230768,11.894615384615385,{"y":12.19,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.02,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.97,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.65,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":14.54,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.39,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.69,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.26,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.94,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.47,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.8,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.56,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.35,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >